Company News
Agios Mitapivat Trial Shows 40.6% Hemoglobin Response
Agios presented 52‑week Phase 3 RISE UP trial results, showing 40.6% of mitapivat patients achieved ≥1 g/dL hemoglobin increase versus 2.9% placebo.
Mitapivat reduced transfusion need by 41.1% relativ
